Post Reports cover image

The promise and peril of ketamine

Post Reports

CHAPTER

Navigating FDA Approval and Off-Label Use of Ketamine for Mental Health

This chapter explores the FDA's cautious approach to ketamine for mental health, focusing on obstacles related to its off-patent status and the implications for clinical trials. It contrasts the unregulated off-label use with the stricter approval process for S-ketamine, emphasizing patient experiences alongside regulatory hurdles.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner